* confirmed sars-cov-2 infection (current or previous) * women who are pregnant or breastfeeding * active hematologic malignancy * any immune deficiency not related to cancer or cancer treatment (e.g. inherited immune deficiency or known infection with human immunodeficiency virus) * systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of vaccination. inhaled or topical steroids, and adrenal replacement steroids (\> 10 mg daily prednisone equivalent) are permitted. in addition, standard of care with short course steroids to prevent nausea and allergic reactions from chemotherapy or iodinated ct contrast is allowed. additional criteria for cohort a: * current or previous diagnosis of a solid malignancy, unless treated with curative intent \>5 years before enrolment and without signs of recurrence during proper follow-up * previous history of a hematologic malignancy additional criteria for cohort b: • treatment with cytotoxic chemotherapy within 4 weeks of vaccination additional criteria for cohort c: • treatment with an ici within 3 months of vaccination

* confirmed sars-cov-2 infection (current or previous) * women who are pregnant or breastfeeding * active hematologic malignancy * any immune deficiency not related to cancer or cancer treatment (e.g. inherited immune deficiency or known infection with human immunodeficiency virus) * systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of vaccination. inhaled or topical steroids, and adrenal replacement steroids (\> 10 mg daily prednisone equivalent) are permitted. in addition, standard of care with short course steroids to prevent nausea and allergic reactions from chemotherapy or iodinated ct contrast is allowed. additional criteria for cohort a: * current or previous diagnosis of a solid malignancy, unless treated with curative intent \>5 years before enrolment and without signs of recurrence during proper follow-up * previous history of a hematologic malignancy additional criteria for cohort b: • treatment with cytotoxic chemotherapy within 4 weeks of vaccination additional criteria for cohort c: • treatment with an ici within 3 months of vaccination

- confirmed sars-cov-2 infection (current or previous) - women who are pregnant or breastfeeding - active hematologic malignancy - any immune deficiency not related to cancer or cancer treatment (e.g. inherited immune deficiency or known infection with human immunodeficiency virus) - systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of vaccination. inhaled or topical steroids, and adrenal replacement steroids (> 10 mg daily prednisone equivalent) are permitted. in addition, standard of care with short course steroids to prevent nausea and allergic reactions from chemotherapy or iodinated ct contrast is allowed. additional criteria for cohort a: - current or previous diagnosis of a solid malignancy, unless treated with curative intent >5 years before enrolment and without signs of recurrence during proper follow-up - previous history of a hematologic malignancy additional criteria for cohort b: • treatment with cytotoxic chemotherapy within 4 weeks of vaccination additional criteria for cohort c: • treatment with an ici within 3 months of vaccination

- confirmed sars-cov-2 infection (current or previous) - women who are pregnant or breastfeeding - active hematologic malignancy - any immune deficiency not related to cancer or cancer treatment (e.g. inherited immune deficiency or known infection with human immunodeficiency virus) - systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medication within 14 days of vaccination. inhaled or topical steroids, and adrenal replacement steroids (> 10 mg daily prednisone equivalent) are permitted. in addition, standard of care with short course steroids to prevent nausea and allergic reactions from chemotherapy or iodinated ct contrast is allowed. additional criteria for cohort a: - current or previous diagnosis of a solid malignancy, unless treated with curative intent >5 years before enrolment and without signs of recurrence during proper follow-up - previous history of a hematologic malignancy additional criteria for cohort b: • treatment with cytotoxic chemotherapy within 4 weeks of vaccination additional criteria for cohort c: • treatment with an ici within 3 months of vaccination